Real-time Estimate
Other stock markets
|
5-day change | 1st Jan Change | ||
14.46 USD | -1.40% | -3.29% | -33.84% |
09/05 | Oppenheimer Adjusts Viridian Therapeutics Price Target to $31 From $36, Maintains Outperform Rating | MT |
09/05 | B. Riley Downgrades Viridian Therapeutics to Neutral From Buy | MT |
This article is reserved for members
Already a member?
Log InNot a member ?
Free registrationEPS Revisions
1st Jan change | Capi. | |
---|---|---|
-33.84% | 936M | |
+27.74% | 49.18B | |
+0.73% | 42.11B | |
+50.47% | 40.37B | |
-5.26% | 28.85B | |
+13.59% | 26.09B | |
-22.52% | 18.71B | |
+7.93% | 13.26B | |
+32.27% | 12.32B | |
-0.18% | 11.99B |
- Stock Market
- Equities
- VRDN Stock
- News Viridian Therapeutics, Inc.
- JMP Securities Adjusts Price Target on Viridian Therapeutics to $44 From $46, Maintains Market Outperform Rating